Mizuho Maintains Buy on WAVE Life Sciences, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has maintained a Buy rating on WAVE Life Sciences (NASDAQ:WVE) and increased the price target from $10 to $19, indicating a positive outlook on the company's stock.
March 12, 2024 | 11:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Salim Syed reaffirmed a Buy rating on WAVE Life Sciences and raised the price target from $10 to $19, signaling strong confidence in the company's future performance.
The increase in price target from $10 to $19 by a reputable analyst suggests a strong bullish sentiment towards WAVE Life Sciences. This adjustment reflects expectations of improved performance or positive developments within the company, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100